Alvotech Doubles Its Humira Copycat Factory Capacity — But Can It Actually Fill the Gap After a Brutal First Half?

Shares of Alvotech jumped 3.8% to ISK 708 Monday after the FDA approved a second production suite at the company's Reykjavik plant for making its Humira biosimilar, SIMLANDI. The new suite doubles manufacturing capacity available to support U.S. supply — welcome news for a company that has spent most of 2026 explaining why it couldn't make enough product.

• A Factory Bottleneck That Cost Real Revenue Is Now Easing. Alvotech's first-half 2026 revenue fell 31% year over year to $212 million, reflecting manufacturing slowdowns during facility improvements and quality-system upgrades.

Management still guides 2026 total revenue of $650–$700 million , meaning roughly $440–$490 million must come in the second half — more than double the first-half haul. The new suite's approval makes that back-loaded target at least physically plausible, but execution risk remains steep.

• The FDA Green Light Signals Broader Regulatory Confidence. The approval follows the FDA's July 2026 closure of its most recent inspection of the Reykjavik facility with a "Voluntary Action Indicated" classification — a passing grade, not a warning. More critically, Alvotech resubmitted U.S. applications for biosimilars to Simponi and Eylea in June, with FDA review decisions anticipated in Q4 2026. A clean manufacturing record strengthens the odds those new products get approved on schedule.

• Market Share Is Still Tiny Despite Huge Ambition. SIMLANDI achieved roughly 10% share of U.S. Humira biosimilar sales, described as the fastest-growing competitor. But total adalimumab biosimilar adoption hit only about 60% as of early 2026 , and the field is crowded — adalimumab alone has 10 FDA-approved biosimilars. Doubling capacity only matters if Alvotech and partner Teva can convert it into prescriptions.

• The Balance Sheet Leaves Little Room for Stumbles. Cash fell to $142.8 million by June 30, down from $172.4 million at year-end 2025.

The company raised roughly $165 million in equity and secured a $75 million term loan to bridge the gap. If the second-half revenue surge doesn't materialize, dilution or more debt looms.

Bottom line: The capacity doubling removes a real manufacturing constraint — but investors are betting on a dramatic second-half acceleration that Alvotech has yet to prove it can deliver.